^
    Back
    Association details:
    Biomarker:RAD51 overexpression
    Cancer:Ovarian Cancer
    Drug Class:PARP inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Cell Int
    Title:

    Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer.

    Published date:
    05/05/2021
    Excerpt:
    High RAD51 expression indicated unfavorable survival outcomes and resistance to platinum, taxane, and PARP inhibitors in ovarian cancer. In the validation cohort (126 patients), high RAD51 expression indicated platinum resistance, and platinum-resistant patients expressed more RAD51. Patients with high RAD51 expression had shorter OS (HR = 2.968, P < 0.0001) and poorer PFS (HR = 2.838, P < 0.0001). RAD51 expression level was negatively correlated with patients' survival length.
    DOI:
    https://doi.org/10.1186/s12935-021-01953-5